CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

Background It is unknown whether patients undergoing primary percutaneous coronary
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …

Individualizing patient treatment is a core objective of the medical field. Reaching this
objective has been elusive owing to the complex set of factors contributing to both disease …

Objectives The aim of this study was to examine the effect of CYP2C19 genotype on clinical
outcomes in patients with coronary artery disease (CAD) who predominantly underwent …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele
nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation …

Background: Although clopidogrel is still frequently used in patients with acute coronary
syndromes (ACS), its efficacy is hampered by interpatient response variability caused by …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …